Medtech Alert

Eloxx Pharmaceuticals, a leader in ribosomal RNA-targeted genetic therapies for rare diseases, have announced the final data assessment from the Phase 2 clinical trial of ELX-02 in combination with ivacaftor in Class 1 Cystic Fibrosis patients with at least one nonsense mutation. In the final assessment, ELX-02 demonstrated clinically relevant improvement in ppFEV1.

Verge Genomics, a clinical-stage biotechnology company transforming drug discovery using artificial intelligence and human data, today announced the completion of the Phase 1 clinical trial of VRG50635 in healthy adult volunteers to help those with ALS.

DEM BioPharma, an immune-oncology company developing therapies that target signals on cancer cells and myeloid phagocytes to eliminate cancer, today announced the addition of Wendy Young to its Scientific Advisory Board. “At DEM Bio, our mission is to pioneer the next generation of immunotherapeutics.

Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that it has entered into a research collaboration with AbCellera for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. Confo will apply its proprietary ConfoBody® technology to stabilize the selected GPCRs in their disease-relevant conformations, which will then be used as antigens to enable antibody discovery and development.

Vyriad announces an expansion of a Phase 1 investigator-initiated trial at Mayo Clinic evaluating the safety and efficacy of Voyager-V1 (VSV-hIFNbeta-NIS) in patients with peripheral T-cell lymphoma (PTCL) following encouraging initial results. Voyager-V1 is an investigational therapy being co-developed with Regeneron Pharmaceuticals, Inc., to treat patients with recurrent or treatment-resistant cancers.

Astellas Pharma and Cullgen have announced a research collaboration and exclusive option agreement to discover multiple innovative protein degraders. Under the terms of the agreement, the two companies aim to develop multiple targeted protein degraders by combining Cullgen’s proprietary uSMITE™ targeted protein degradation platform featuring novel E3 ligands with Astellas’ drug discovery capabilities.

Auxilius Pharma has consolidated its funding of $1 Million for developing its lead asset, AUX-001, an innovative new medication for treating chronic-stable angina pectoris in the US, a condition affecting 11 million Americans over the age of 20. The company raised late last year USD 1MM in a seed financing round led EU based by venture capital fund CofounderZone.

Captivate Bio and EverCell Bio are excited to announce a new collaboration to accelerate the development of pluripotent stem cell derived technologies. Built on the strengths of both companies, this collaboration brings together a shared vision for delivering unique and custom services paired with custom reagents to accelerate research for discovery in regenerative medicine.

Applied StemCell and the California Institute for Regenerative Medicine (CIRM) have partnered as Industry Resource Partners. ASC is offering its IP-based gene insertion technology and TARGATT iPSC master cell line, along with resources to support cell therapy process development and GMP manufacturing, to CIRM Translational and Clinical awardees.

, the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today the FDA cleared an IND application for ALE.C04 as a monotherapy and in combination with pembrolizumab, in a first-in-human clinical trial in recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) that is expected to start during the second half of 2023. “With ALE.C04 we aim to treat solid tumors in a unique way.